In the claims:

Please amend the following claims as indicated.

1-27. **(Cancelled)**

28. **(Currently amended)** A method for inducing an immune response ~~a host to produce Ab3 antibodies that specifically bind to prostate specific antigen~~ comprising administering to ~~the host an Ab1~~a mammal an antibody or antigen-binding fragment thereof that specifically binds to an epitope of circulating prostate specific antigen, said epitope being an epitope to which ~~wherein the epitope is specifically bound by~~ a monoclonal antibody produced by a hybridoma that has ATCC Designation Number HB-12526 specifically binds.

29. **(Cancelled)**

30. **(Currently amended)** The method of claim 28, wherein the ~~Ab1~~ antibody is a monoclonal antibody ~~produced by a hybridoma that has ATCC Designation Number HB-12526~~.

31. **(Cancelled)**

32. **(Currently amended)** The method of claim 28, wherein the ~~Ab1~~ antibody or antigen-binding fragment thereof is conjugated to an immunogenic carrier.

33. **(Previously presented)** The method of claim 32, wherein the immunogenic carrier is keyhole limpet hemocyanin.

34-35. **(Cancelled)**

36. **(Currently amended)** The method of claim 28, wherein the ~~Ab1~~ antibody is selected from ~~the group consisting of one member of an immunologic pair; an antibody;~~ a monoclonal antibody,[[;]] ~~an antibody fragment thereof;~~ a single chain antibody[[;]], a humanized antibody, ~~or fragment thereof;~~ and a chimeric antibody ~~or fragment thereof~~.

~~37~~ 6. **(Currently amended)** The method according to claim ~~17 or 28~~ 1, wherein the ~~Ab1~~ antibody or antigen binding fragment thereof is a xenogenic antibody or antigen-binding fragment thereof.

~~38~~ 7. **(Currently amended)** The method according to claim ~~17 or 28~~ 1, wherein the ~~Ab1~~ antibody or antigen-binding fragment thereof is formulated with an adjuvant.

39. **(Cancelled)**

~~40~~ 8. **(Currently amended)** The method of claim ~~39 28~~ 1, wherein the ~~low dose~~antibody or antigen-binding fragment thereof is formulated at a dose of from about 0.1 μg to about 2 mg per kilogram of body weight of the ~~patient~~mammal.

~~41~~ 9. **(Currently amended)** The method of claim ~~39 28~~ 1, wherein the ~~low dose~~ antibody or antigen-binding fragment thereof is formulated at a dose of from about 1.0 μg to about 200 μg per kilogram of body weight of the ~~patient~~mammal.